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ABSTRACT 
DNA methyltransferase (DNMT) 1 is a critical enzyme which is mainly responsible 
for conversion of unmethylated DNA into hemimethylated DNA. Previous studies 
have suggested that enzymes related to DNA methylation play a very important role 
in liver fibrosis. In this study, we identified a significant over-expression of DNMT1 
in activated hepatic stellate cells (HSCs), which suggests a vital function of DNMT1 
in HSCs transactivation. Interestingly, ligand activation of peroxisome 
proliferator-activated receptor gamma (PPAR-γ) in activated HSCs led to efficient 
down-regulation of DNMT1 expression. Furthermore, the PPAR-γ ligand 
rosiglitazone (RSG) dramatically down-regulated the expression of DNMT1 and 
up-regulated the expression of PPAR-γ during the transactivation of primary rat HSCs, 
suggesting an important role of PPAR-γ in HSC transactivation. Reporter assays 
showed that ligand activation of PPAR-γ inhibited transcriptional activation of the 
human DNMT1 gene promoter and such inhibition was rescued by transfection of 
nuclear factor-kappaB (NF-κB) expression vector pCMV-p50 and pCMV-p65, which 
indicates that PPAR-γ suppress DNMT1 expression via negatively interfering with 
NF-κB binding activity on DNMT1 promoter. Conclusion: These studies suggest that 
PPAR-γ may play a role in inhibiting HSCs transactivation by suppressing expression 
of DNMT1. 
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1. CHAPTER ONE: INTRODUCTION 
1.1 Purpose of Study 
The purpose of this study is aiming at elucidating the role of DNMT1 in HSC 
activation and the potential of PPAR-γ activation as a novel approach in inhibiting the 
expression of DNMT1 for the treatment of liver fibrosis. 
1.2 Background 
1.2.1 Liver Fibrosis 
Fibrosis is a severe systemic disease characterized by excessive accumulation of 
fibrous connective tissues, such as collagen
1
. Fibroproliferative diseases occur 
throughout the human body; lungs, kidneys, and liver are among the most common 
affected organs. The chronic and severe progression of fibrosis results in the failure of 
the physiological functions of tissues. Liver fibrosis has been extensively investigated 
because its long-lasting progression can result in hepatocellular carcinoma (HCC), 
which is the fifth most common cancer worldwide
2,3
. Hence, it is important to 
understand the biological mechanisms involved in liver fibrogenesis to develop 
effective treatments. 
Liver fibrogenesis is a dynamic wound-healing process characterized by excessive 
production and deposition of extracellular matrix (ECM), mainly type I and III 
collagen, in the liver interval space between sinusoidal endothelial cells and 
hepatocytes
4
. As a result, ECM proteins progressively accumulate in liver parenchyma 
and form permanent fibrous scars distorting the normal hepatic architecture
5
.  
To date, remarkable progress has been made in understanding the pathophysiology 
of liver fibrosis at the cellular level. It has been established that the activation of 
hepatic stellate cells (HSCs), a type of nonparenchymal cell resident in the space of 
Disse, is the essential event in liver fibrogenesis, playing a pivotal role through 
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transdifferentiating into myofibroblasts
4
. Many studies have suggested that the HSC 
activation involve a number of cytokines and chemokines and the interaction between 
HSCs and other cell types
6
. It is believed that Kupffer cells, resident macrophages of 
liver sinusoids, are first activated by several types of liver injuries. The 
proinflammatory response triggers the activation of HSCs resulting in excessive 
proliferation of myofibroblasts and stimulation of ECM synthesis, eventually leading 
to liver fibrosis
1,7
. 
1.2.2 Hepatic Stellate Cells (HSCs) 
HSCs represent approximately 15% of the cells in normal liver. Under 
physiological conditions, HSC stay as quiescent and store up to 85% of the body's 
vitamin A as lipid droplets
7,8
. When freshly isolated and cultured, quiescent HSCs 
display several characteristics including a low proliferative rate, low fibrogenic 
potential, little cytokine secretion, and lack of contractile
7,9
. 
Upon liver injury of various causes, HSCs undergo a process termed activation or 
transdifferentiation, whereby they change from non-proliferating state to a highly 
proliferative, fibrogenic, proinflammatory, and contractile myofibroblasts resulting in 
the overproduction of collagen-rich ECM
9
. During the activation, HSCs lose vitamin 
lipid droplets. Additionally, the migrating and fast-proliferating features of these 
activated HSCs perpetuate hepatic inflammation at the sites of liver injury
8,10
. 
Potential therapeutic targets for the treatment of liver fibrosis have been suggested 
according to the different features of activated HSCs (Figure. 1). These features 
include:  
a) Activation and accumulation of activated HSCs at the sites of liver injury;  
b) Alteration of the balance of collagen synthesis and degradation, leading to net 
collagen accumulation by HSCs
5
. 
c) Contractile response to vasoactive molecules, leading to increases in portal 
vasoresistance. 
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Activation of HSCs is the primary culprit in liver fibrogenesis. Studies with rat 
HSCs have shown that low levels of messenger RNA (mRNA) encoding procollagen I 
and III are observed in quiescent HSCs, whereas these genes are significantly 
upregulated in activated HSCs both in vitro and in vivo. In activated HSCs, dramatic 
increases in the mRNA stability of procollagens might be one of the most important 
factors among other mechanisms
7,11
. 
Therefore, strategies that inhibition HSCs activation might be of importance in 
attenuating fibrogenic response. In the last decades, a number of studies have 
examined the cellular and molecular mechanisms underlying HSC activation: The 
initiation phase of this process is due primarily to paracrine stimuli from injured 
neighboring cells, which include hepatocytes, Kupffer cells, sinusoidal endothelial 
cells, platelets, and infiltrating inflammatory cells
7,12,13
. Lipid peroxides produced by 
hepatocytes and Kupffer cells lead to oxidative stress and promote HSC activation
14,15
. 
Moreover, cytokines released by damaged neighboring cells can also activate HSCs, 
through stimulating various signaling pathways such as Sp1, c-myb, nuclear factor κB 
(NF-κB), c-jun/AP1, and STAT-1, which regulate the expression of a number of genes 
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that are involved in the progression of liver fibrosis
16-19
. Activated HSCs perpetuate 
their own activation through several autocrine loops, including the secretion of 
TGF-β1 and an up-regulation of its receptors20. 
 
1.2.3 Peroxisome Proliferator-Activated Receptor Gamma 
(PPAR-γ) 
The peroxisome proliferator-activated receptors (PPARs) belong to the superfamily 
of steroid/thyroid hormone nuclear receptors. Four isoforms of PPARs have been 
identified, namely PPARα, β, γ and δ, which regulate transcription of a number of 
target genes controlling numerous important physiological processes
21
. PPAR-γ has 
been extensively studied and shown to be implicated in various biological functions in 
various types of cells. Specifically, ligand activation of PPAR-γ can result in growth 
inhibition and/or apoptosis of fibroblasts
22
. 
PPAR-γ interacts with co-repressor proteins and inhibits gene expression in the 
absence of ligands. Upon activation by cognate ligands, PPAR-γ releases the 
co-repressor and translocates from cytoplasm to the nucleus where it recruits 
co-activator proteins and forms a heterodimer with retinoid X receptor-α (RXR-α). 
This multi-protein complex then binds to peroxisome proliferator response elements 
(PPRE), leading to transcriptional activation
23
. 
Much attention has been paid to the anti-inflammatory and protective effects of 
PPAR-γ during wound-healing. PPAR-γ regulates gene transcription involved in the 
tissue repair process of many organs, thereby ameliorating inflammation, oxidative 
stress, and matrix remolding
24
. Furthermore, studies have suggested that PPAR-γ 
might be an important molecular target in modulating in liver fibrosis. Its 
transcriptional dysfunction has been shown to be critically involved in liver fibrosis
25
. 
PPAR-γ has been identified to be a key transcription factor in controlling HSC 
activation and the associated changes in phenotypes. Expression of PPAR-γ protein is 
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dramatically reduced in activated HSCs both in vitro (human and rat cell lines) and in 
vivo (isolated rat HSCs)
26-28
. Mechanistic investigations have shown that PPAR-γ 
plays an important role in maintaining the quiescence status of HSCs through 
regulation of a panel of adipogenic transcription factors, including CCAAT/enhancer 
binding protein (C/EBP), liver X receptor-α (LXR-α), and sterol regulatory 
element-binding proteins-1c (SREBP-1c), all of which are rapidly diminished during 
HSC transdifferentiation
29
. 
It is known that PPAR-γ expression is downregulated during HSC activation, while 
PPAR-γ-cognate ligands inhibit profibrogenic and proinflammatory activities in HSCs, 
decrease collagen accumulation rate, and enhance collagenase activity in the injured 
liver
26,28
. Specifically, the treatment of culture-activated HSC with the natural or 
synthetic ligands for PPAR-γ suppresses many key functional parameters of the cell 
activation, including cell proliferation, expression of collagen, TGF-β1, α-smooth 
muscle actin (α-SMA), monocyte chemotactic protein-1(MCP-1) genes, and 
chemotaxis
26,28,31
. Importantly, treatment with the PPAR ligands ameliorates both 
induction of fibrosis and progression of preexisting fibrosis in various animal 
models29. These effects were reproducible when exposing activated HSCs to a variety 
of different PPAR-γ agonists and were abrogated in HSCs treated with a PPAR-γ 
antagonist
30
, suggesting that the effects are mediated PPAR-γ. 
  Moreover, PPAR-γ regulation on adipogenic transcription in HSCs also occurs at 
the chromatin-packaging level. Studies showed that the DNA methylation inhibitor 
5‟-azacytidine (5-azadC) blocked HSC myofibroblastic transdifferentiation and 
prohibited the diminished expression of PPAR-γ in activated HSCs31. 
In summary, the above studies suggest an important role of PPAR-γ in regulating 
HSCs activation and the anti-fibrotic role of PPAR-γ ligands. In fact, forced ectopic 
expression of PPAR-γ expression in activated HSCs and PPAR-γ agonists treatment 
have exhibited dramatic therapeutic benefits for experimental liver fibrosis in various 
animal models
32-34
. 
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1.2.4 DNA Methylation & DNA Methyltransferase (DNMT) 
1 
In mammals, DNA methylation occurs in the cytosine residues at the C5 position, 
primarily in the CG dinucleotides and occasionally at non-CG sites
35
. DNA 
methylation is a key process in epigenetic regulation of the expression of many 
gene
36 , 37
, parental imprinting regulation
38 - 40
, X chromosome inactivation 
stabilization
41-44
, and maintenance of the genome integrity through protection against 
endogenous retroviruses and transposons
45,46
. 
DNMT1, localized at DNA replication foci during the S phase
47
, was the first 
mammalian DNA methyltransferase enzyme to be cloned
48
 and biochemically 
characterized
49
. DNMT1 shows a preference for hemimethylated DNA over 
unmethylated DNA
50,51
. A role of DNMT1 as a maintenance methyltransferase has 
been well demonstrated, as well as its responsibilities on the preservation of the 
methylation patterns during cell divisions by methylation of hemimethylated CG 
dinucleotides produced by DNA replication
49
. 
Recently, the progression of liver fibrosis has been reported to be associated with 
hypermethylation of DNA
52
. HSCs activation is inhibited by 5-azadC, a DNA 
methylation inhibitor
53
. The loss of expression of IκBa and PPAR-γ, genes that are 
believed to maintain the quiescent phenotype of HSCs, which occurs during 
transdifferentiation, is also prevented by 5-azadC, which suppress the acquisition of 
proinflammatory and profibrogenic characteristics in activated HSCs
54
. Furthermore, 
several studies using heterozygous mice revealed that the inhibitor of DNA 
methyltransferase Dnmt1, 5‟-azadC, also ameliorated renal fibrosis via inhibiting 
proliferation of myofibroblasts
55,56
. These results suggest a pivotal role of DNA 
hypermethylation in the progression of both liver and renal fibrosis
57
. 
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1.2.5 NF-κB 
In the past few decades, nuclear factor-kappaB (NF-κB) has been characterized to 
be one of the most crucial transcription factors that are involved in the regulation of 
various important genes. It has been demonstrated that NF-κB pathway is involved in 
several important events such as the control of cell survival, differentiation, and 
proliferation
58
. In addition, NF-κB activation has been shown to be implicated in 
obesity
59
, malignancy
60
 and other diseases59
59
. Subsequent studies have shown that 
increased activation of NF-κB leads to enhanced expression of various 
proinflammatory mediators
61
,
62
. 
NF-κB activation is controlled by a number of positive and negative regulatory 
elements. The most common regulation pathway is the IκB regulation. In the 
„„resting‟‟ state, NF-κB dimers stay as an inactive from in the cytoplasm through 
association with IκB proteins. Upon activation via various types of stimuli, the IκB 
kinase complex becomes activated, leading to phosphorylation, ubiquitination, and 
degradation of IκB proteins. Once IκB is detached from NF-κB complex, the 
remaining NF-κB dimers translocate to the nucleus, bind to specific DNA sequences, 
and promote transcription of target genes
58
. 
In hepatic fibrogenesis, NF-κB is activated during the transdifferentiation of 
HSCs
63
, and NF-κB responsive genes are induced in the activated HSCs64. It has been 
demonstrated that activation of HSCs is closely associated with the transcription 
factor NF-κB activation, even though a causal relationship between NF-kB and HSCs 
activation is not fully understood. NF-κB induces the transcription of several genes 
involved in liver injury and activation of HSCs, such as MIP-2, MCP-1, CINC, 
ICAM- and IL-6
63
. NF-κB has also been shown to have protective function of 
TNFα-mediated apoptosis in several cell types65,66. In addition, diminution of IκBa is 
critically involved in transdifferentiation since this results in reprogramming of basal 
NF-κB activity to have a elevated level that drive the expression of a number of 
proinflammatory genes and render the cells resistant to apoptosis
67,68
. 
Connection has been built between PPAR-γ and NF-κB. For example, treatment 
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with a PPAR-γ ligand, rosiglitazone, results in a rapid and consistent suppression of 
the proinflammatory transcription factor NF-κB in MNCs69. 
Furthermore, recent studies have suggested that mouse DNMT1 is a target for the 
zinc finger protein Sp1
70
, which also serves as a broad transcriptional co-regulator for 
NF-κB. The disruption of Sp1/NF-κB mediated DNMT1 transactivation in human 
acute myeloid leukemia (AML) can effectively cause DNMT1 down-regulation and 
DNA hypomethylation and transcription of methylation-silenced genes
71
. Based on 
the above studies, we hypothesize that PPAR-γ negatively regulates DNMT1 
expression through inhibiting NF-κB signaling pathway. 
 
 
1.3 Key Words 
Hepatic Stellate Cells (HSCs); DNA Methyltrasferase (DNMT) 1; Peroxisome 
proliferator-activated receptor gamma (PPAR-γ); nuclear factor-kappaB (NF-κB); 
gene regulation. 
 
2. CHAPTER TWO: MATERIAL AND 
METHODS 
2.1 Materials 
Rosiglitazone were purchased from Sigma (St Louis, Mo). All products for cell 
culture were purchased from Invitrogen (Carlsbad, Calif). pGL3 and pCMX-βgal 
were described previously
72,73
. phDNMT1-Luc was generated following lab protocol. 
Expression plasmids, Expression plasmids, PPAR-γ expression vector was kindly 
provided by Dr. Wen Xie (University of Pittsburgh, Pittsburgh, PA). NF-κB 
expression vector p50 & p65 was kindly provided by Dr. Xian Ming Chen (Creighton 
University Medical Center, Omaha, NE). 
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2.2 Cell Culture 
LX-2 and CV-1 cells were cultured in DMEM medium supplemented with 10% FBS, 
streptomycin (100μg/mL) and penicillin (100U/mL). When treated with Rosiglitazone, 
LX-2 and CV-1 cells were cultured in DMEM medium supplemented with 1% FBS. 
Isolated Rat primary HSCs were cultured in DMEM supplemented with 10% FBS, 
streptomycin (100μg/mL) and penicillin (100U/mL). 
 
2.3 Animals and HSCs Isolation 
Retired male Sprague-Dawley rats were used for primary HSC isolation. HSCs were 
isolated via in situ proteinase/collagenase perfusion followed by density gradient 
centrifugation as described
74
. Primary cells were used at 5–7 days and were more than 
95% pure. Cells were grown on standard tissue culture plastic dishes in DMEM with 
10% fetal bovine serum and antibiotics. 
 
2.4 Plasmid Construction 
Human DNMT1 promoter containing fragment (-3190kb) was amplified by PCR with 
the oligonucleeotides 5`-CGGGTACCCGGGGATGTACCAAACGGAGAG-3` 
(forward primer) and 5`- CGCTCGAGCGACACAGCAAGACCCCATCTC-3` 
(reverse primer) using a human genomic chromosome clone (provided by Dr. Jiang Li, 
University of Pittsburgh, Pittsburgh, PA) as template. The fragment was cloned into 
pGL3-basic vector (Promega, Fitchburg, WI) after digestion with enzymes XhoI and 
KpnI (Biolab, Conyers, GA), and the resulting plasmid was named as phDNMT1-Luc. 
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2.5 RT PCR and Real-time PCR 
Total RNA was extracted from cells with TRIzol reagent (Invitrogen, Carlsbad, CA) 
and the first-strand cDNA was synthesized using SuperScript III reverse transcriptase 
(Invitrogen, Carlsbad, CA). PCR amplification of DNMT1 was then performed as 
described by product SOP protocol. 
Real time PCR assay of PPAR-γ and DNMT1 was performed with lab SOP protocol. 
Real-time PCR analysis was performed by use of SYBR Green-based assays with the 
ABI 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA). 
Amplification was performed under the following conditions: 50°C for 2 min, 95°C 
for 10 min, and 40 cycles of 95°C for 15 s, and 60°C for 1 min. Transcript abundance, 
normalized to β-glucuronidase expression, was expressed as fold increase over a 
calibrated sample. 
 
2.6 Western Blot Analysis for DNMT1 
Protein extraction and Western Blot analysis were performed as described by 
supplemental SOP protocol. Rabbit polyclonal IgG anti-DNMT1 antibody and 
secondary Goat anti rabbit IgG-HRP antibody were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). The ECL chemiluminescence kit were purchased 
from Amersham Biosciences (Piscataway, NJ). 
 
2.7 Transient Transfection and Luciferase Assay 
CV-1 cells were grown to 60% to 70% confluence in 96-well plates. Cells were 
transiently transfected using InstantFect (Synthesized by Dr. Xiang Gao, University of 
Pittsburgh, PA) with luciferase reporters in the presence or absence of pGL3. The 
DNMT1 promoter fragment was cloned into pGL3-Basic luciferase vector (Pomega, 
Madison, WI). pGL3 was added to ensure identical amounts of DNA in each well. 
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Cells were transfected for overnight with 0.1 μg of this construct. Transfection 
efficiency was monitored by cotransfection of pCMX-βgal plasmid and transfection 
of EGFL plasmid in separate wells. Cell extracts were prepared after transfection, and 
the luciferase and β-galactosidase assays were performed as described, and luciferase 
activity was normalized β-galactosidase activity. Transfection experiments were 
performed at least 3 times in triplicate. Data were represented as fold induction over 
reporter gene alone.  
 
2.8 Statistical Analysis 
All data are expressed as means_SEM unless otherwise stated. Comparisons between 
2 groups were made with unpaired Student‟s t test. Comparisons between 3 or more 
groups were made with ANOVA followed by Tukey–Kramer post hoc analysis. In all 
cases, P<0.05 was considered statistically significant. 
 
3. CHAPTER THREE: RESULTS  
3.1 Enhanced expression of DNMT1 in activated 
HSCs. 
Recent studies have suggested a number of important functions of DNA 
methylation in HSCs activation in liver and kidney fibrosis
55,57
. Further study in 
kidney fibrosis has indicated a pivotal function of DNMT1 in HSCs activation
55
.Thus, 
we hypothesized that DNMT1 plays a vital role in HSCs activation, and the 
up-regulated expression of DNMT1 facilitates the subsequent expression of 
pro-fibrosis-related genes in activated HSCs. 
Then, in order to determine the importance of DNMT1 gene expression in HSCs 
activation, we first examined the DNMT1 mRNA expression in quiescent HSCs 
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which were isolated from rat liver tissue. Meanwhile, isolated quiescent HSCs were 
cultured in DMEM medium with 10%FBS for 7 days. After 7days, cultured-activated 
primary rat HSCs were examined by Real-Time PCR assay to examine the mRNA 
expression level. Figure 2 shows that the DNMT1 mRNA level is significantly 
up-regulated in quiescent HSCs compared to activated HSCs, which demonstrated 
that HSCs activation is associated with upregulation of DNMT1 gene expression. This 
suggested an important role of DNMT1 in HSCs activation.  
To further support our observation, we collected the liver tissue from long-term and 
short-term CCl4 treated mice, and examined the DNMT1 mRNA expression by 
Real-Time PCR. Normally, short-term treatment of CCl4 leads to liver centrizonal 
necrosis and steatosis
75
, while prolonged administration results in liver fibrosis, and 
eventually cirrhosis
76
. Results demonstrate that DNMT1 expression is significantly 
enhanced in long-term treatment group when compared to control group, while no 
difference is detected in the short-term treatment group, indicating that DNMT1 
up-regulation may contribute to liver fibrosis development instead of acute 
inflammatory response (Figure 3). 
All the above results have suggested a vital role of up-regulated DNMT1 in HSCs 
activation. 
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Figure 2, Expression of DNMT1 during HSCs trans-activation. Isolated rat HSCs were cultured in 
complete medium overnight following isolation. The mRNA of DNMT1 in quiescent HSCs was 
collected and analyzed with real-time RT-PCR. In a separate experiment, cells were cultured in 
10% FBS DMEM medium for 7 days to allow transactivation. mRNA expression of DNMT1 in 
activated HSCs was similarly examined by real-time RT-PCR. *P < 0.01 vs. control group. 
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Figures 3, DNMT1 expression in liver of mice receiving short-term and long-term treatment of 
CCl4. Liver tissues were homogenized and DNMT1 mRNA expression was examined by RT-PCR. 
**P < 0.01 vs. control group. 
 
3.2 Rosiglitazone (RSG) treatment down-regulates 
DNMT1 expression in HSCs. 
Previous Studies showed that DNA methylation inhibitor 5‟-azacytidine (5-azadC) 
blocked HSC myofibroblastic transdifferentiation and prohibited the diminished 
expression of PPAR-γ in activated HSCs77. Hence, evidences suggested a potential 
correlation between PPAR-γ and DNA methylation. Since our data have shown that 
there is negative correlation between PPAR-γ and DNMT1 expression, thereby, we 
hypothesized that PPAR-γ activation may play a direct role in the regulation of 
DNMT1 expression. 
To investigate the biological function of PPAR-γ in DNMT1 regulation, we 
examined whether RSG activation of PPAR-γ can down-regulate DNMT1 expression 
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in activated HSCs. We selected LX-2 cell line because it has been described to have 
comparable features with human HSCs
78
. RSG is a member of the thiazolidinedione 
class of drugs, which selectively bind to PPAR-γ79. We tested the mRNA expression 
of DNMT1 in LX-2 cells after RSG treatment. Figure 4 shows that RSG treatment 
results in a significantly decreased expression of DNMT1 mRNA in a 
concentration-dependent manner. Interestingly, in cultured-activated primary rat HSCs, 
the treatment groups with RSG exhibited a dramatic suppression of DNMT1 gene 
expression in activated HSCs when compared to DMSO-treated group (Figure 5). 
To further confirm manipulation of DNMT1 gene expression by PPAR-γ activation, 
Western Blot assay was conducted to examine the DNMT1 protein expression level in 
HSCs. As shown in Figure 6, DNMT1 (183kD) protein expression level were 
inhibited in a concentration-dependent manner in LX-2 cells after RSG treatment, 
which is consistent with mRNA study.  
 
 
 
Figure 4, Regulation of DNMT1 expression by RSG treatment in LX-2. LX-2 were grown to 70% 
confluence in the complete medium and then cultured in the conditioned medium in the presence 
of indicated concentrations of RSG or vehicle DMSO (0.1%). After 24hrs, the mRNA was 
extracted and DNMT1 expression was analyzed by real-time RT-PCR. *P < 0.05, **P < 0.01 vs. 
DMSO. Data are mean±SEM from 3 assays performed in triplicate. 
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Figure 5, Regulation of DNMT1 expression with RSG treatment during HSCs activation. Isolated 
rat HSCs were cultured in complete medium for 24hrs following isolation. Cells were then 
cultured in conditional medium in the presence of RSG or vehicle DMSO (0.1%) for 7 days. The 
ligand-containing medium was changed every 48hrs. The expression levels of DNMT1 mRNA 
were examined via real-time RT-PCR at day 1 and day 7, respectively. *P < 0.05, **P < 0.01 vs. 
expression level in quiescent HSCs. Data are mean±SEM from two assays performed in duplicate. 
 
 
  
Figure 6, Regulation of DNMT1 protein expression with RSG treatment.  DNMT1 expression 
was examined via Western Blot analysis 24 h following RSG treatment. β-actin was used as a 
loading control. 
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3.3 PPAR-γ treatment rescues the expression of 
PPAR-γ during HSCs activation 
Recent study has suggested that once the HSCs are activated, the activated 
phenotype can be reversed into quiescent phenotype by forced expression of PPAR-γ 
via an adenoviral vector
80
. Thereby, we hypothesized whether the treatment of RSG 
during HSCs activation can recover the expression of PPAR-γ. Again, we tested the 
mRNA expression level of PPAR-γ from isolated rat HSCs. Figure 7 suggests that 
once quiescent HSCs become activated, the expression of PPAR-γ is highly 
suppressed, which is consistent with previous report80. We then compared the 
expression of PPAR-γ in activated rat HSCs from RSG treated group and DMSO 
treated group. As shown in figure 7, treatment of RSG during HSCs activation can 
rescue the PPAR-γ expression in culture-activated primary rat HSCs. This observation 
suggests an important role of RSG at the early-stage of liver fibrosis: RSG treatment 
can effectively inhibit DNMT1 expression and recover the PPAR-γ expression in 
activated HSCs. 
In addition, we hypothesized whether the treatment of RSG could rescue the 
expression of PPAR-γ in fully activated human HSCs. At first, we tested the effect of 
PPAR-γ recovery efficiency after RSG 24hrs treatment. As shown in Figure 8, we 
failed to observe any changes of PPAR-γ expression in LX-2 cells. Thus, extended 
treatments were performed as 48hrs and 96hrs. Once again, no significant changes on 
PPAR-γ gene expression have been observed after the treatment (Figure 8). Thereby, 
the observations suggest that RSG treatment may not be able to rescue the expression 
of PPAR-γ in activated HSCs. We believe this may due to the low expression level of 
PPAR-γ presented in the activated HSCs, which leads to a minimized effect of 
PPAR-γ ligand activation. 
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Figure 7, Regulation of PPAR-γ expression with RSG treatment during HSCs activation. Isolated 
rat HSCs were cultured in complete medium for 24hrs following isolation. Cells were then 
cultured in conditional medium in the presence of RSG or vehicle DMSO (0.1%) for 7 days. The 
ligand-containing medium was changed every 48hrs. The expression levels of PPAR-γ mRNA 
were examined via real-time RT-PCR at day 1 and day 7, respectively. *P < 0.05, **P < 0.01 vs. 
expression level in quiescent HSCs. Data are mean±SEM from two assays performed in duplicate. 
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Figure 8, Effect of RGS treatment on PPAR-γ gene expression in LX-2. LX-2 were grown to 70% 
confluence in the complete medium and then cultured in the conditioned medium in the presence 
of indicated concentrations of RSG or vehicle DMSO (0.1%). The total mRNA was extracted after 
different time periods as shown in the figures and PPAR-γ expression was analyzed by real-time 
RT-PCR. *P < 0.05, **P < 0.01 vs. DMSO. Data are mean±SEM from 3 assays performed in 
triplicate. 
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3.4 PPAR-γ represses transcriptional activation of the 
human DNMT1 promoter 
Down-regulation of DNMT1 mRNA expression under RSG treatment suggests that 
activation of PPAR-γ modulates DNMT1 expression at transcriptional level. We then 
hypothesized that ligand activation of PPAR-γ repress DNMT1 expression via 
exerting its inhibitory activity on DNMT1 promoter. To verify our hypothesis, we 
constructed a luciferase reporter expression plasmid (phDNMT1-Luc) that is driven 
by human DNMT1 promoter. As normally described, the promoter is predicted to 
locate within the 3kb upstream from transcriptional starting site70. Thus, we cloned the 
3kb gene sequence of human DNMT1 promoter and cloned into pGL3 luciferase 
reporter vector.  
Afterwards, CV-1 cells were co-transfected with constructed phDNMT1-Luc and 
PPAR-γ expression plasmid, and then treated with RSG for another 24hrs. Also, we 
tested the transfection efficiency by EGFL reporter vector. Fluorescence examination 
suggested that our transfection efficiency had reached 30%-40%, which shows a 
convincing transfection efficiency to support our further study. As shown by Figure 9, 
the treatment of RSG shows a significant inhibitory effect on DNMT1 promoter 
activity in a concentration-dependent manner. Hence, this observation has indicated 
that ligand activation of PPAR-γ inhibits DNMT1 expression via repressing DNMT1 
promoter activity. 
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Figure 9, DNMT1 promoter transcriptional activity under RSG treatment. CV-1 cells were 
transiently co-transfected with phDNMT1-Luc and PPAR-γ expression vector at a molar ratio of 
3:1. Five hours later the transfection medium was replaced with complete medium and cells were 
incubated for 12 hours. Cells were then cultured in the conditioned medium in the presence of 
indicated concentration of RSG or vehicle DMSO (0.1%) for 24hrs. Luciferase assay was then 
performed. Data shown in the panels represent mean (SD) from triplicate assays. *P < 0.05, 
**P<0.01 vs. the cells treated with DMSO. 
 
 
3.5 RSG reduces the NF-κB binding activity  
Since we have observed that ligand activation of PPAR-γ can effectively suppress the 
activity of DNMT1 promoter, we then conducted further studies to search for possible 
molecular mechanisms involved in this regulation. After searching DNMT1 promoter 
binding sites, we failed to identify any PPAR-γ binding consensus sequence. Instead, 
a few potential NF-κB binding sites have been predicted in the promoter. It has been 
shown that NF-κB is one of the most important transcriptional factors involved in 
regulation of DNMT1 expression71. It was postulated that PPAR-γ can inhibit activity 
of NF-κB through competition of limited availability of co-factors81. We thereby 
hypothesized that inhibition of DNMT1 expression is mediated by reduction of 
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NF-κB activity upon PPAR-γ activation. Thus, we co-transfected the phDNMT1-Luc, 
PPAR-γ expression plasmid and p50 & p65 NF-κB expression vectors into CV-1 cells, 
and examined the luciferase activeity after RSG treatmenr for 24hrs. As shown in 
Figure 10, the group with NF-κB over-expression has weakened the inhibitory effect 
of DNMT1 promoter activity by RSG treatment. The observation verified our 
hypothesis that PPAR-γ suppresses the DNMT1 promoter activity by interfere the 
NF-κB binding activity. 
 
 
 
 
Figure 10, DNMT1 promoter transcriptional activity under RSG treatment with or without NF-κB 
over-expression. The darker bars represent groups transfected with only phDNMT1-Luc, while the 
lighter bars represent groups co-transfected with both phDNMT1-Luc and NF-κB. CV-1 cells 
were transiently co-transfected with phDNMT1-Luc, PPAR-γ expression vector and NF-κB 
expression vector p50 & p65 at a molar ratio of 3:1:1, respectively. Five hours later the 
transfection medium was replaced with complete medium and cells were incubated for 12 hours. 
Cells were then cultured in the conditioned medium in the presence of indicated concentration of 
RSG or vehicle DMSO (0.1%) for 24hrs. Luciferase assay was then performed. Data shown in the 
panels represent mean (SD) from triplicate assays. **P < 0.01 vs. the cells treated with DMSO. 
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4. CHAPTER FOUR: DISCUSSIONS 
In this study, we have clearly demonstrated increased expression of DNMT1 in 
activated HSCs, which further provides additional important information about DNA 
methylation function in the HSCs activation. As one of the most important 
maintenance methyltransferase, DNMT1 exhibits vital functions in silencing genes, 
such as PPAR-γ. To date, most information about DNA methylation and DNMT1 are 
related to cancer oncogenesis, only few recent studies have studied the role of DNA 
methylation in liver fibrosis57. MeCP2 has been demonstrated to be a critical 
epigenetic regulator of liver fibrosis and HSCs activation53. Thus, our study provides 
more evidence on a role of DNA methylation in HSCs, which involves DNMT1. 
PPAR-γ, as one of the most studied nuclear receptors, has been studied extensively 
in liver fibrosis, but limited information is available on its function on DNA 
methyltransferase genes. In this study, we demonstrated the ligand activation of 
PPAR-γ leads to down-regulation of DNMT1 expression in activated HSCs. Moreover, 
PPAR-γ showed more effect on DNMT1 expression in HSCs than other nuclear 
receptors such as RAR and FXR (data not shown).  
As mentioned in previous studies, DNA methylation plays a pivotal role in HSCs 
activation57. Animal studies demonstrated that DNMT1 over-expression is involved in 
liver fibrosis rather than liver centrizonal necrosis or steatosis. Our study also shows 
that DNMT1 expression is over-expressed during HSCs activation. Therefore, it 
would be very beneficial if the expression of DNMT1 can be suppressed before 
quiescent HSCs become activated. Interestingly, we have shown that PPAR-γ 
activation can prevent up-regulation of DNMT1 during HSCs activation.  
 In addition, it is very exciting to notice that Rosiglitazone mediated PPAR-γ 
activation can significantly recover the PPAR-γ expression during HSCs activation. 
This observation has suggested the importance of PPAR-γ ligand treatment at the 
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early-stage of liver fibrosis due to PPAR-γ function recovery and inhibitory effect on 
DNMT1 expression.  
 The mechanism of DNMT1 down-regulation by PPAR-γ activation is not fully 
understood. Computational analysis did not reveal any PPAR-γ binding consensus 
sequence in either rat or human DNMT1 promoter region, suggesting that it is 
unlikely that PPAR-γ inhibits DNMT1 expression via directly interacting with 
DNMT1 promoter. Previous study has suggested that PPAR-γ may inhibit gene 
expression via interference of AP-1, STAT, and NF-κB signaling pathways via 
competition for essential cofactors81. In our study, we demonstrated the fact that 
PPAR-γ down-regulates DNMT1 gene expression by interfering NF-κB binding 
activity on DNMT1 promoter, and we suggest that a potential biological mechanism 
involved in this observation: via interfering NF-κB binding activity by competing 
co-factors of NF-κB.  PPAR-γ reduces the binding activity of NF-κB on DNMT1 
promoter. Also, other studies suggest several possible signaling pathways, for instance, 
AP-1 signaling through inhibition of c-Jun or c-Fos binding to an AP-1 site may also 
act as a potential regulator
82
. Also, people have suggested that in a PPAR-γ dependent 
or independent way, PPAR-γ ligand 15-Deoxy-Δ12,14-prostaglandin J2 can interfere the 
NF-κB binding activity by inhibit the degradation of IκBα enzyme, which results in 
the enhancement of IκBα in the cells, and leads to the impaired binding activity by 
NF-κB 83 , 84 . Therefore, more studies are needed to better illustrate the role of 
interaction of PPAR-γ with NF-κB transcriptional factors and its essential co-factors 
in PPAR-γ mediated inhibition of DNMT1 expression in HSCs. 
  Results from this study have provided a novel mechanism of PPAR-γ ligands 
effect on liver fibrosis, which may guide future therapeutical design for liver fibrosis 
treatment.  
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6. APPENDIX: PROTOCOL 
6.1 mRNA extraction and Real-time PCR 
Day 1: Extraction of mRNA and reverse transcription: 
1. Remove culture from 6-well plate. 
2. Add 1mL Trizol into each well of 6-well plate, mix and incubate at room 
temperature for 5min. Transfer the solution into Ep tubes. 
3. Add 200μL Chloroform, shake with hands for 15s, and incubate at room 
temperature for 2-3 min until the two layers separated. Centrifuge at 4℃, 12000 
rpm for 15min. 
4. Transfer the colorless supernatant to another tube. (Take out the supernatant from 
top to bottom, slowly pipet up. Usually 450-500μL can be taken out. Some 
protein may between the layers, don‟t take the protein!) Add the same volume of 
isopropanol, and then shake with hands for 1 min. Centrifuge at 4℃, 12000 rpm 
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for 15 min. 
5. Pour out the supernatant, and add 75% alcohol (~800μL to wash), shake a few 
times.  Centrifuge at 4℃, 12000 rpm for 15 min. 
6. Remove the supernatant (pour out, be gentle), Centrifuge at 4℃, 12000 rpm for 5 
min. Pipet to remove residual supernatant. Air-dry 5-10 min until pellets become 
transparent. 
7. Add 15μL water ( autoclaved ultra-pure water), to each tube, mix and transfer 
11μL sample to another tube (0.3mL small tubes in line) 
8. Add 1μL dNTP and 1μL Oligo dT primer (for binding to poly-A tail) to each 
sample. (make master-mixture of dNTP and Oligo dT is helpful to decrease 
variation) 
9. Incubate for 5min at 55-60℃, and then put the tubes on ice immediately, then 
wait at least 2min.(This step is to let AAA bind to TTT. Poly-A might be 
separated with Oligo dT if temperature drops slowly) 
10. 5*FS (first-strand cDNA) buffer 4μL, 0.1M DTT 2.5μL (proteinase inhibitor, 
prevernt degradation of reverse transcriptase), Superscript III 0.5μL (reverse 
transcriptase), and then add 7μL mixture to each tube. (Total volume of each 
sample 11+1+1+7=20μL. Make master mixture for sample number+1) 
11. RT (reverse transcription): 1.5hrs (program: A9). Continue with Real Time PCR 
or store the sample in -20℃. 
 
Day2: Real-time PCR 
1. Dilute the samples 4-folds with water. 
2. 20μL Syber Green system: (2*master mix 10μL, water 7uL, primer 1μL)*(sample 
number+1), +sample 2μL. Master mix contains enzyme, dNTP, buffer and Syber 
Green. Be careful: never touch the bottom or upper side of the plate with finger. 
3. Cover the film, press each edge with flat plate and let it attach tightly. 
4. Centrifuge for twice. For the first time, centrifuge briefly and shake by tapping 
the edges and centrifuge for 5min, 2500 rpm. 
5. Put the plate in Real-time machine. Set up: the name, volume of the sample and 
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location, save. Choose the “dissociation curve”. 
 
 
6.2 Western Blot 
SDS-page preparation: 
1. Clean the apparatus 
2. Join the two glasses (thick & thin) together and fit them into plastic holder 
(Bio-rad), then in stand 
3. Prepare polyacrylamide gel: 
 
Resolving gel: 
40% acrylamide mix 
10% SDS 
10% APS (make fresh each time) 
1.5 M Tris, pH 8.8 (resolving gel) 
TEMED 
Then mix and load to frame, and add isopropanol above that: to remove bubbles 
 
Stacking gel: 
40% acrylamide mix 
10% SDS 
10% APS (make fresh each time) 
1.0 M Tris, pH 6.8 (stacking gel) 
TEMED 
Pour out the isopropanol before adding stacking gel, then load the stacking gel and put 
comb on top of it. 
Wait at least 30min to check if it is solidfied, and then wrap it in plastic bag and put it 
in 4℃ 
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Sample preparation: 
1. Remove medium, wash with PBS 1X twice 
2. Add loading & lyses buffer 
3. Scratch and mix with the back side of the tips 
4. Transfer to eppendorf tubes and put the eppendorf tubes on heating block. 
Keep the temperature above 95℃ for 10min, open the lid every 3min to 
prevent water pop. 
5. Put the tubes on ice for use or store in -20℃ 
 
Sample loading:  
1. Prepare electrophoresis buffer 
2. Fill the buffer full in inner chamber, fill outer chamber half-full 
3. Take out the comb, and load the samples into the holes of the resolving gel 
4. Continue filling buffer to full 
5. Close lid and run for 80v when in resolving gel,after cross the stacking gel, 
change to 120v. 
 
Transfer gel to membrane: 
1. Prepare filter paper and membrane by cutting to appropriate size; for each gel 
prepare two filter paper and one membrane 
2. Take membrane with blunt-end forceps carefully (don‟t touch membrane with 
hands); put the membrane into methanol for 1-2min 
3. Then put into transfer buffer and soak until the gel electrophoresis is ready. For 
filter papers, soak in transfer buffer with membrane 
4. After gel electrophoresis finished, cut gel with clean razor blade to appropriate 
size 
5. Use the forceps to put the gel on top of membrane carefully, and cover them with 
filter paper up and down 
6. Take this “sandwich” to transfer cassette: semi-dry transfer method 
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7. Cover the lid and run 15v for 35 min (wet cassette with transfer buffer and swipe 
by tissue before cover the lid ) 
 
Staining: 
1. Take out membrane into DD H2O, wash and remove water 
2. Pour little of red staining buffer, shake for a while, and check the bands to see if 
we have equal amount of proteins loading. 
3. Wash membrane with PBST to get rid of staining buffer and color, change PBST 
every 10min, and shake for at least 30min until color fades out. 
 
Blocking: 
1. Prepare blocking buffer (5g non-fat milk into 100ml PBST) 
2. Put membrane into blocking buffer and shake for 1hr. 
 
Applying primary antibody 
1.  Dilute primary antibody 1:1000 for DNMT1 antibody, 1:4000 for β-actin into 
blocking buffer, total volume 15ml 
2. Put membrane into the shaking cases and shake overnight at 4℃. 
 
Applying secondary antibody 
1. Take out membrane, and wash with PBST 3 time for 5min each. 
2. Dilute secondary antibody 1:10000 in PBST 20ml 
3. Put the membrane into the shaking cases and shake for 1hr. 
4. Remove PBST and dry with tissue 
 
Photo image: 
1. Put membrane onto plastic sheet in the Western Blot cassette 
2. Spray image enzyme substrate onto the membrane 
3. Wrap plastic sheet on membrane and remove the bubbles 
4. Cover cassette , go to the dark room 
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5. Take one negative film and put it on top of the plastic wrap, seal the cassette for 
3min and exposure in developing machine. Adjust image quality by extend or 
shorten nagetive film exposure time.  
 
6.3 Transformation 
A. make competent cell 
1. Inoculate one colony from LB plate into 2ml LB liquid medium. Shake at 37℃ 
overnight 
2. Inoculate 1ml overnight cell culture into 100ml LB medium (in a 500ml flask). 
3. Chill the culture on ice for 15min. also make sure the 0.1M CaCl2 solution and 
0.1M CaCl2 plus 15% glycerol are on ice 
4. Centrifuge the cells for 10min at 3300g at 4℃. 
5. Discard the medium and resuspend the cell pellet in 30-40 ml cold 0.1M CaCl2. 
6. Keep the cells on ice for 30 min 
7. Centrifuge the cells as above 
8. Remove the supernatant, and resuspend the cell pellet in 6ml 0.1M CaCl2 solution 
plus 15% glycerol 
9. Pipet 0.4-0.5 ml of the cell suspension into sterile 1.5ml micro-centrifuge tubes. 
Freeze these tubes on dry ice and then transfer them to -80℃ freezer. 
 
B. transformation protocol using heat shock 
1. Take competent E.coli cells from -80℃, and turn on water bath to 42℃. 
2. Put competent cells in a 1.5 ml tube. For transforming a DNA construct, use 50μl 
of competent cells. For transforming a ligation, use 100μl of competent cells.  
3. Keep tubes on ice. 
4. Add 50ng of circular DNA into E.coli cells. Incubate on ice for 10 min. to thaw 
competent cells. 
5. Put tubes with DNA and E.coli into water bath at 42℃ for 45 seconds. 
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6. Put tubes back on ice for 2min to reduce damage to the E.coli cells 
7. Add 1ml of LB (with no antibiotic added). Incubate tubes for 1 hour at 37℃. 
8. Spread about 100μl of the resulting culture on LB plates (with Ampicillin 
antibiotic added) grow overnight. 
9. Pick colonies about 12-16 hrs later. 
6.4 phDNMT1-Luc vector ligation 
1. Prepare insert DNMT1 3Kb DNA fragment using PCR methods. Design 
appropriate primes and use human genomic DNA as template. 
2. Select restriction enzymes for insert and vector, and determine the appropriate 
reaction buffers. 
3. Combine the following in a microfuge tube (30μL total volume): 
2μg DNA (insert or vector) 
1μL each restriction enzyme 
3μL 10x buffer 
3μL10x BSA (if recommended) 
xμL H2O (to bring total volume to 30μL) 
4. Incubate tubes at 37℃ for 1 hour 
5. Run all of the samples on a gel to check whether the restriction enzyme cutting is 
successful, and then purify the DNA using Invitrogen Gel Extraction Kit. 
6. Ligation: combine the following in a microgfuge tube (10μL total volume): 
1μL Vector DNA 
5μL Insert DNA 
1μL 10x Ligase Buffer 
1μL T4 DNA Ligase 
2μL H2O (to bring total volume to 10μL) 
Tip: try different vector to insert ratios to optimize ligation reaction  
7. Incubate at 16℃ for 2 hours, or at 4℃ overnight (follow the manufacturer‟s 
instructions). 
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8. Transformation and check colonies 
 
6.5 Transfection 
1. Prepare the following solution with 0.7μl X 4 =2.8μl “Instantfect” on a 96 well 
plate, and then add 100μl Opti-MEM without serum 
2. Make up DNA working solution: add 1.32μg DNA in 100μl Opti-MEM without 
serum 
3. Mix up the above two solution, let them stay in the hood for at least 15 min. 
4. Wash CV-1 cells with PBS without Ca2+, Mg2+, and then removes the PBS. 
5. Digest CV-1 with 1X Trypsin-EDTA, incubate the plate at 37℃ for 3-5 min until 
cells get loose. 
6. Resuspend in 5ml DMEM, and spin wth 1500g X 5min 
7. Remove the supernatant carefully; add 3ml Opit-MEM and 3ml DMEM to mix 
cells into suspension. 
8. Add 200μl cell suspension to the well with DNA and “Instantfect”, and then mix 
well. Next, aliquote 100μl into each well. 
9. Incubate at 37℃ for 5hrs, and then remove the medium. Change to complete 
DMEM medium and culture overnight. 
6.6 Luciferase assay 
Preparation of luciferase lysis buffer 
 
96well/96 samples 
96 x 0.15 = 14.4 ml, so we prepare 16ml for 96 well plate 
 
16 x 0.001 =16μl of 1M DTT 
16 x 0.008 =128μl of IM MgCl2 
16 x 0.04 =640μl of 0.1M EGTA (pH 8.0)  
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16 x 0.0016 =25.6μl of 0.25M PMSF 
 
β-gal assay buffer base 
 
To make 4L 
Na2HPO4 (Sigma S0876): 34.08g 
KCl (Fisher P217-3): 2.9824g 
0.5M MgCl2: 8ml 
Add MQH2O to 4L, no pH adjustment 
 
Preparation of β-gal assay buffer 
Volume calculation the same as luciferase (each plate use 10ml, calculate total volume 
and add 2ml.) 
V x 3.5μl of beta-macarporthaol 
V x 0.0025g of ONPG 
Add 12ml base buffer base 
 
Lyse cell 
 
150μl of lysis buffer added, shake for 5-10 min 
 
50μl to clear plate/flat bottom (Corning from Fisher 07-200-90), add 100μl of β-gal 
buffer, shake, and incubate at 37℃, measure β-gal activity. 
 
50μl to white/flat bottom plate (Corning from Fisher 07-200-591), add 100μl 
luciferase buffer, shake, and measure luciferase activity. 
 
Luciferase assay buffer base 
 
To make 1L 4x solution: 
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Tricine (Sigma T9784): 14.34g 
Magnesium Carbonate (Sigma M0125): 2.08g 
MgSO4 (Sigma M5921): 2.63g 
0.5M EDTA: 800μl 
Use H2O to bring the volume to 1L 
 
Preparation of Luciferase assay buffer 
 
96 x 0.1 =9.6ml, so we prepare 12ml 
 
Total volume (V) 
V x 0.25 of 4x base 
V x 0.69 of MQ H2O 
V x 0.005 of 0.1M ATP 
V x 0.005 of 1M DTT 
V x 0.05 of 0.01M Luciferin in methanol (D-luciferin Firefly, Biosynth L-8200: 
methanol, Fisher A412-4) 
V x 1.5μl of 0.1g/ml co-enzyme A in water (co-enzynme A Calbiochem #234101, 1g) 
 
6.7 Rat Hepatic Stellate Cell Isolation 
1. Prepare 50 ml GBSS without NaCl and HBSS with Ca2+ containing 50mg 
protease and 25mg collagenase type IV. Then warm up in 37℃ water bath 
2. Anesthetize rat (put rat in chamber with isoflurane for 3-5 min), then fix its limbs 
with needles 
3. Open abdomen, being careful not to puncture diaphragm, cut and move gut to the 
outside. 
4. Perfuse the liver via portal vein canula. With 37℃ HBSS at 10/min flow rate. The 
color of liver changed while perfusing. 
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5. Recirculate HBSS solution containing digestion enzymes, first 10rcf/min until 
35ml, change the rate to 3rcf/min. Total last time should be 30 min or more. 
6. Collect and cut the liver into suspension with scissors and forceps (add HBSS 
without Ca
2+
 to suspend) 
7. Then filter suspension into 4 tubes, add HBSS without Ca2+to bring up the 
volume to 50ml in each tube. Afterwards, centrifuge under the condition of 
1400rcf/min, 7min, 4℃ 
8. Genteelly pour out the supernatant, be careful not to disturb the cell pellets 
9. Prepare Nycodenz solution 14.7g +51ml GBSS without NaCl 
10. Prepare 0.3% BSA: 5ml 3% BSA + 45ml HBSS without Ca2+ 
11. Suspend pellet with 10ml 0.3% BSA + 8ml Nycodenz, shake with hands genteelly, 
and split the suspension into six 15-ml tubes. 
12. Add 2-3ml HBSS above the suspension very slowly and carefully to bring the 
total volume to 14ml, make sure the HBSS is clear above the suspensions. 
13. Then centrifuge at 1400rcf/min, 4℃ for 25mins 
14. Suck out the clear HBSS layer we added at last step very carefully 
15. We can white cells pellets floating in the first layer of suspension, so use the pipet 
to take out all the cells at this layer. Then, resuspend in HBSS and centrifuge at 
1400rcf/min 4℃ for 7min 
16. Remove supernatant and split the remaining into 4-6 dishes with complete 
DMEM medium and culture overnight 
17. Change the medium into fresh complete medium at the second day. 
 
 
 
 
 
 
 
 
 
 
 
 41 
 
7. BIBLIOGRAPHY 
                                                             
1
 Bataller R, Brenner DA: Liver fibrosis. J Clin Invest. 2005, 115(2):209-218. 
2
 Iredale JP: Models of liver fibrosis: exploring the dynamic nature of inflammation 
and repair in a solid organ. J Clin Invest. 2007;117(3):539–548. 
3
 Llovet JM: Updated treatment approach to hepatocellular carcinoma. Journal of 
gastroenterology 2005, 40(3):225-235. 
4
 S.L. Friedman: Nature Reviews. Gastroenterology & Hepatology 7 (2010) 425-437. 
5
 Bataller R, DA, Brenner: Hepatic Stellate Cells as a Target for the Treatment of 
Liver Fibrosis. Semin Liver Dis. 2001 Aug;21(3):437-51. 
6
 Hernandez-Gea V, Friedman S.L: Pathogenesis of liver fibrosis. Annu Rev Pathol. 
2011;6:425-456. 
7
 Maher JJ, Zia S, Tzagarakis C: Acetaldehyde-induced stimulation of collagen 
synthesis and gene expression is dependent on conditions of cell culture: studies with 
rat lipocytes and fibroblasts. Alcohol Clin Exp Res 1994 Apr;18(2):403–409 
8
 Friedman SL: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of 
the liver. Physiol Rev. 2008 Jan;88(1):125-72. 
9
 Rockey DC, Housset CN, Friedman SL: Activationdependent contractility of rat 
hepatic lipocytes in culture and in vivo. J Clin Invest 1993;92:1795–1804 
10
 Wu J, Zern MA: Hepatic stellate cells: a target for the treatment of liver fibrosis. J 
Gastroenterol 2000;35:665–662 
11
 Stefanovic B, Hellerbrand C, Holcik M, Briendl M, Aliebhaber S, Brenner DA:. 
Posttranscriptional regulation of collagen alpha1(I) mRNA in hepatic stellate cells. 
Mol Cell Biol 1997;17:5201–5209 
12
 Friedman SL, Arthur MJ: Activation of cultured rat hepatic lipocytes by Kupffer 
cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of 
cell proliferation via induction of platelet-derived growth factor receptors. J Clin 
Invest 1989;84:1780–1785 
13
 Gressner AM, Lahme B, Brenzel A: Molecular dissection of the mitogenic effect of 
hepatocytes on cultured hepatic stellate cells. Hepatology 1995;22:1507–1518 
14
 Poli G: Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 
2000;21:49–98 
15
 Britton RS, Bacon BR. Intracellular signaling pathways in stellate cell activation. 
Alcohol Clin Exp Res 1999;23(5):922–925 
16
 Reimann T, Hempel U, Krautwald S, Axmann A, Scheibe R, Seidel D, Wenzel KW: 
Transforming growth factor-beta1 induces activation of Ras, Raf-1, MEK and MAPK 
in rat hepatic stellate cells. FEBS Lett 1997; 403(1):57–60 
17
 Pinzani M, Gesualdo L, Sabbah GM, Abboud HE: Effects of platelet-derived 
growth factor and other polypeptide mitogens on DNA synthesis and growth of 
cultured rat liver fatstoring cells. J Clin Invest 1989;84:1786–1793 
18
 Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C, Housset C: 
Cellular localization of endothelin-1 and increased production in liver injury in the rat: 
potential for autocrine and paracrine effects on stellate cells. Hepatology 
1998;27(2):472–480 
19
 Marra F, Arrighi MC, Fazi M, Caliqiuri A, Pinzani M, Romanelli RG, Efsen E, 
Laffi G, Gentilini P: Extracellular signalregulated kinase activation differentially 
regulates plateletderived growth factor‟s actions in hepatic stellate cells, and is 
 42 
 
                                                                                                                                                                              
induced by in vivo liver injury in the rat. Hepatology 1999;30(4): 951–958 
20
 Friedman SL, Yamasaki G, Wong L: Modulation of transforming growth factor beta 
receptors of rat lipocytes during the hepatic wound healing response. Enhanced 
binding and reduced gene expression accompany cellular activation in culture and in 
vivo. J Biol Chem 1994;269:10551–10558 
21
 Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ: Nuclear receptors and lipid 
physiology: opening the X-files. Science, 2011; 294: 1866-1870. 
22
 Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, 
Standiford TJ, Thannickal VJ, Reddy RC: PPAR-gamma agonists inhibit profibrotic 
phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am 
J Physiol Lung Cell Mol Physiol. 2008 May;294(5):L891-901. 
23
 Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, 
Schwabe JW: Structural basis for the activation of PPARgamma by oxidized fatty 
acids. Nat Struct Mol Biol. 2008 Sep;15(9):924-31. 
24
 Michalik L, Wahli W: Involvement of PPAR nuclear receptors in tissue injury and 
wound repair. The Journal of Clinical Investigation 2006; 116(3):598-606. 
25
 Wagner M, Zollner G, Trauner M: Nuclear receptors in liver disease. Hepatology 
2011;53(3): 1023-1024 
26
 Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors 
and hepatic stellate cell activation. J Biol Chem 2000;275:35715–22. 
27
 Galli A, Crabb D, Price D, Ceni E, Salzano R, Surrenti C, Casini A: Peroxisome 
proliferator-activated receptor g transcriptional regulation is involved in 
platelet-derived growth factor-induced proliferation of human hepatic stellate cells. 
Hepatology 2000;31:101–8. 
28
 Marra F, Efsen A, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi 
A, Caporale R, Laffi G, Pinzani M, Gentilini P: Ligands of peroxisome 
proliferator-activated receptor g modulate profibrogenic and proinflammatory actions 
in hepatic stellate cells. Gastroenterology 2000;119:466–78. 
29
 She H, Xiong S, Hazra S, Tsukamoto H: Adipogenic transcriptional regulation of 
hepatic stellate cells. J Biol Chem. 2005 Feb 11;280(6):4959-4967. 
30
 Mann DA, Smart DE: Transcriptional regulation of hepatic stellate cell activation. 
Gut 2002;50:891–896 
31
 Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA: Regulation of 
myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for 
wound healing and fibrogenesis. Cell Death and Differentiation 2007 
Feb;14(2):275-85. 
32
 Yu J, Zhang S, Chu ES, Go MY, Lau RH, Zhao J, Wu CW, Tong L, Zhao J, Poon 
TC, Sung JJ: Peroxisome proliferator-activated receptors gamma reverses hepatic 
nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. 
Int J Biochem Cell Biol. 2010 Jun;42(6):948-57. 
33
 Tomita K, Azuma T, Kitamura N, Nishida J, Tamiya G, Oka A, Inokuchi S, 
Nishimura T, Suematsu M, Ishii H: Pioglitazone prevents alcohol-induced fatty liver 
in rats through up-regulation of c-Met. Gastroenterology 2004 Mar;126(3):873-85. 
34
 Bae MA, Rhee SD, Jung WH, Ahn JH, Song BJ, Cheon HG: Selective inhibition of 
activated stellate cells and protection from carbon tetrachloride-induced liver injury in 
rats by a new PPARgamma agonist KR62776. Archives of Pharmacal Research 2010 
Mar;33(3):433-442. 
35
 Lister R., Pelizzola M., Dowen, R.H, Hawkins, R.D., Hon, G., Tonti-Filippini, J., 
Nery, J.R., Lee, L., Ye, Z., Ngo, Q-M., Edsall, L., Antosiewicz-Bourget, J., Stewart, R., 
 43 
 
                                                                                                                                                                              
Ruotti, V., Millar, A.H., Thomson, J.A., Ren, B. and Ecker, J.R. (2009) Human DNA 
methylomes at base resolution show widespread epigenomic differences. Nature. 
462:315-322 
36
 Miranda TB, Jones PA: DNA methylation: the nuts and bolts of repression. J Cell 
Physiol. 2007 Nov;213(2):384-90. 
37
 Lande-Diner L, Zhang J, Ben-Porath I, Amariglio N, Keshet I, Hecht M, Azuara V, 
Fisher AG, Rechavi G, Cedar H: J. Biol. Chem. 2007, 282, 12194 –12200. 
38
 Delaval K, Feil R: Epigenetic regulation of mammalian genomic imprinting. Curr. 
Opin. Genet. Dev. 2004, 14: 188 –195. 
39
 Hore TA, Rapkins RW, Graves JA: Construction and evolution of imprinted loci in 
mammals. Trends Genet. 2007, 23: 440 –448. 
40
 Sha K: A mechanistic view of genomic imprinting. Annu. Rev. Genomics Hum. 
Genet. 2008, 9: 197 –216. 
41
 Heard E: Recent advances in X-chromosome inactivation. Curr. Opin. Cell Biol. 
2004, 16: 247– 255. 
42
 Chang SC, Tucker T, Thorogood NP, Brown CJ: Mechanisms of X-chromosome 
inactivation. Front. Biosci. 2006, 11: 852– 866. 
43
 Yen ZC, Meyer IM, Karalic S, Brown CJ: A cross-species comparison of 
X-chromosome inactivation in Eutheria. Genomics 2007, 90: 453 – 463. 
44
 Straub T, Becker PB: Dosage compensation: the beginning and end of 
generalization. Nat Rev Genet. 2007 Jan;8(1):47-57. 
45
 Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A: Activation and transposition of 
endogenous retroviral elements in hypomethylation induced tumors in mice. 
Oncogene 2008, 27: 404 –408. 
46
 Yoder JA, Soman NS, Verdine GL, Bestor TH: DNA 
(cytosine-5)-methyltransferases in mouse cells and tissues. Studies with a 
mechanism-based probe. J Mol Biol. 1997, 270: 385– 395. 
47
 Leonhardt H, Page AW, Weier HU, Bestor TH: A targeting sequence directs DNA 
methyltransferase to sites of DNA replication in mammalian nuclei. Cell 1992, 71: 
865– 873. 
48
 Bestor T, Laudano A, Mattaliano R, Ingram V: Cloning and sequencing of a cDNA 
encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of 
the mammalian enzymes is related to bacterial restriction methyltransferases. J. Mol. 
Biol. 1988, 203: 971 –983. 
49
 Jurkowska RZ, Jurkowski TP, Jeltsch A: Structure and Function of Mammalian 
DNA Methyltransferases. Chembiochem. 2011 Jan 24;12(2):206-22. 
50
 Fatemi M, Hermann A, Pradhan S: The activity of the murine DNA 
methyltransferase Dnmt1 is controlled by interaction of the catalytic domain with the 
N-terminal part of the enzyme leading to an allosteric activation of the enzyme after 
binding to methylated DNA. J Mol Biol. 2001, 309: 1189– 1199. 
51
 Goyal R, Reinhardt R, Jeltsch A: Accuracy of DNA methylation pattern 
preservation by the Dnmt1 methyltransferase. Nucleic Acids Res. 2006, 34: 1182 – 
1188. 
52
 Friedman SL: Mechanism of Hepatic Fibrogenesis. Gastroenterology 2008, 
134:1655-1669. 
53
 Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA: Regulation of 
myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for 
wound healing and fibrogenesis. Cell death and differentiation 2007, 14(2):275-285. 
54
 Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA: Regulation of 
 44 
 
                                                                                                                                                                              
myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for 
wound healing and fibrogenesis Cell Death and Differentiation (2007) 14, 275–285 
55
 Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, Salant DJ, 
Muller CA, Kalluri R, Zeisberg M: Methylation determines fibroblast activation and 
fibrogenesis in the kidney. Nature medicine 2010, 16(5):544-550. 
56
 Ortiz A, Ucero AC, Egido J: Unravelling fibrosis: two newcomers and an old foe. 
Nephrol Dial Transplant 2010, 25(11):3492-3495. 
57
 Komatsu Y, Waku T, Iwasaki N, Ono W, Yamaguchi C, Yanagisawa J: Global 
analysis of DNA methylation in early-stage liver fibrosis. BMC Med Genomics. 2012 
Jan 27;5:5. 
58
 Hayden MS, Ghosh S: NF-kB, the first quarter-century: remarkable progress and 
outstanding questions. Genes Dev. 2012 26: 203-234 
59
 Baker RG, Hayden MS, Ghosh S: NF-kB, inflammation, and metabolic disease. 
Cell Metab 2011 Jan 5;13(1):11-22. 
60
 Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-kB as the 
matchmaker. Nat Immunol 2011 Jul 19;12(8):715-23 
61
 Sun Z, Andersson R: NF-kB ACTIVATION AND INHIBITION: A REVIEW. 
SHOCK, 2002 Aug;18(2):99-106. 
62
 Lawrence T: The nuclear factor NF-kB pathway in inflammation. Cold Spring 
Harb Perspect Biol 2009 Dec;1(6):a001651. 
63
 Lang A, Schoonhoven R, Tuvia S, Brenner DA, Rippe RA: Nuclear factor KB in 
proliferation, activation, and apoptosis in rat hepatic stellate cells. Journal of 
Hepatology 2000 Jul;33(1):49-58 
64
 Hellerbrand C, Wang SC, Tsukamoto H, Brenner DA, Rippe RA: Expression of 
intercellular adhesion molecule 1 by activated hepatic stellate ceils. Hepatology 1996; 
24: 670-6. 
65
 Baeuerle PA, Baltimore D: NF-kappaB: ten years after. Cell 1996; 87: 13-20. 
66
 Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of 
TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 787-9. 
67
 Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, 
Millward-Sadler H, Wright MC, Mann DA: Inhibition of inhibitor of kappaB kinases 
stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver 
fibrosis. Gastroenterology 2005; 128: 108–120. 
68
 Oakley F, Mann J, Ruddell RG, Pickford J, Weinmaster G, Mann DA: Basal 
expression of IkappaBalpha is controlled by the mammalian transcriptional repressor 
RBP-J (CBF-1) and its activator Notch1. J Biol Chem 2003; 278: 24359–24370. 
69
 Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, 
Dhindsa S, Dandona P: Evidence for a Potent Antiinflammatory Effect of 
Rosiglitazone. J Clin Endocrinol Metab, June 2004, 89(6):2728–2735 
70
 Kishikawa S, Murata T, Kimura H, Shiota K, Yokoyama KK: Regulation of 
transcription of the Dnmt1 gene by Sp1 and Sp3 zinc finger proteins. Eur J Biochem. 
2002;269:2961-2970. 
71
 Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki 
M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, 
Caligiuri MA, Chan KK, Wu LC, Marcucci G: Bortezomib induces DNA 
hypomethylation and silenced gene methyltransferase activity in acute myeloid 
leukemia transcription by interfering with Sp1/NF- kB-dependent DNA. Blood. 2008 
Feb 15;111(4):2364-73 
72
 Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman 
 45 
 
                                                                                                                                                                              
DJ, Evans RM: An essential role for nuclear receptors SXR/PXR in detoxification of 
cholestatic bile acids. Proc Natl Acad Sci U S A. 2001;98:3375–3380. 
73
 Groskreutz DJ, Sherf BA, Wood KV, Schenborn ET: Increased Expression and 
Convenience with the New pGL3 Luciferase Reporter Vectors. Promega Notes 
Magazine Number 50, 1995, p.02 
74
 Liu C, Gaca MD, Swenson ES, Vellucci VF, Reiss M, et al. Smads 2 and 3 are 
differentially activated by transforming growth factor-beta (TGF-beta) in quiescent 
and activated hepatic stellate cells. Constitutive nuclear localization of Smads in 
activated cells is TGF-beta-independent. J Biol Chem. 2003;278:11721–11728. 
75
 Pierce RA, Glaug MR, Greco RS, Mackenzie JW, Boyd CD, Deak SB: Increased 
procollagen mRNA levels in carbon tetrachloride-induced liver fibrosis in rats. J Biol 
Chem 1987, 262:1652-8. 
76
 Perez Tamayo R: Is cirrhosis of the liver experimentally produced by CCl4 and 
adequate model of human cirrhosis? Hepatology 1983, 3:112-20. 
77
 Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA: Regulation of 
myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for 
wound healing and fibrogenesis. Cell Death and Differentiation 2007 
Feb;14(2):275-85. 
78
 Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, 
Friedman SL, Eng FJ: Human hepatic stellate cell lines, LX-1 and LX-2: new tools 
for analysis of hepatic fibrosis. Gut. 2005 Jan;54(1):142-51. 
79
 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer S: 
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome 
proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 
1995;270:12953-12956 
80
 Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, Tsukamoto H: 
Peroxisome Proliferator-activated Receptor Induces a Phenotypic Switch from 
Activated to Quiescent Hepatic Stellate Cells. J Biol Chem. 2004 Mar 
19;279(12):11392-401. 
81
 He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins 
S, Pitt B, Xie W, Li S: Downregulation of Endothelin-1 by Farnesoid X Receptor in 
Vascular Endothelial Cells. Circulation Research 2006, 98:192-199 
82
 Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, 
Staels B: Peroxisome proliferator-activated receptor activators inhibit 
thrombin-induced endothelin-1 production in human vascular endothelial cells by 
inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394–402. 
83
 Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM: A 
prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma 
and promotes adipocyte differentiation. Cell 1995;83:813–819. 
84
 Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy 
LL, Ghosh G, Glass C: 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps 
in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 2000;97:4844–4849. 
